Your email has been successfully added to our mailing list.

×
0.0145681581685745 1.84844624287227E-16 1.84844624287227E-16 0.0143080124869928 0.0403225806451614 1.84844624287227E-16 1.84844624287227E-16 1.84844624287227E-16
Stock impact report

Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal

Adamas Pharmaceuticals, Inc. (ADMS) 
Last adamas pharmaceuticals, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.adamaspharma.com/investors
Company Research Source: GlobeNewswire
EMERYVILLE, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that results of its Phase 2 proof-of-concept clinical trial of ADS-5102 (amantadine) extended release capsules in multiple sclerosis (MS) patients with walking impairment were published online in Multiple Sclerosis Journal. Clinical data from the four-week, placebo-controlled, proof-of-concept study showed a statistically significant 17 percent improvement in walking speed from baseline and that a greater proportion of ADS-5102-treated patients experienced at least a 20 percent improvement in walking speed from baseline. The publication can be accessed at: http://journals.sagepub.com/doi/full/10.1177/1352458518754716 “In this proof-of-concept study, a greater proportion of ADS-5102 patients had at least a 20 percent improvement in walking speed compared with the placebo group,” stated Jeffrey A. Cohen, M.D., Mellen Center for Multiple Sclerosis Treatment and Research, Ne Show less Read more
Impact Snapshot
Event Time:
ADMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ADMS alerts
Opt-in for
ADMS alerts

from News Quantified
Opt-in for
ADMS alerts

from News Quantified